摘要
目的:探讨米非司酮对子宫肌瘤患者血清中IGF-1表达的影响。方法:将52例至少有1个瘤体≥3mm的子宫肌瘤治疗组患者,自月经来潮第5天开始,口服米非司酮25mg,1次/d,连续服用3个月。分别测定服药后不同时间点血清IGF-1的浓度,同时用B超检测服药前后子宫肌瘤体积。对照组为绝经前子宫肌瘤患者。结果:不同时间点血清IGF-1水平治疗组与对照组比较差异有统计学意义(P<0.01);治疗组中,服药1.5个月时血清IGF-1水平与其他时间点分别进行比较,差异有统计学意义(P<0.01);服药2、2.5、3个月不同时间点之间血清IGF-1水平比较,差异无统计学意义(P>0.05)。服药后治疗组患者肌瘤体积较对照组显著小,差异有统计学意义(P<0.01)。服用米非司酮后血清IGF-1下降与肌瘤缩减呈显著正相关性。结论:米非司酮能有效降低患者血清中IGF-1的表达。
Objective： To study the effects of mifepristone on the expression of IGF-1 in sera of patients with myoma of uterus.Methods： 52 patients with one tumor body greater than or equal to 3 mm at least, who oraled mifepristone 25 mg per day for taking 3 months since fifth days of menstruation, the serum concentrations of IGF-1 were determined at different time points after taking mifepristone, uterine fibroid volume were detected with B ultrasound before and after taking mifepristone at the same time, the control group was premenopausal patients of hysteromyoma.Results： IGF-1 were significant statistical difference compared treated group with control group in different timcs（P〈O.O1）; there were significant statistical difference compared treated group in 1.5 month with other different times（P〈O.01）; there were no significant statistical difference compared mifepristone treated groups in 2, 2.5, and 3 months（P〉O.O5）.Myoma volume in treated group was significantly reduced after taking medicine compared with the control group（P〈O.O1）.There was a strong positive correlation between serum IGF-1 decrease after taking mifepristone with uterus myoma shrink.Conclusion： Mifepristone can effectively reduce the expression of IGF-1 in serum of patients with hysteromyoma.
出处
《中外医学研究》
2013年第21期3-5,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
米非司酮
IGF-1
子宫肌瘤
Mifepristone
Insulin like growth factor 1
Hysteromyoma
